Opportunities for applying biomedical production and manufacturing methods to the development of the clean meat industry

Clean meat (meat grown using cell culture methods, rather than obtained from animal slaughter) is an emergent biotechnology industry that will ameliorate the serious environmental, sustainability, global public health, and animal welfare concerns of conventional animal agriculture. Critical Technology Elements (CTEs) for clean meat include immortalized cell lines for meat animals (e.g. chicken, pig, cattle, and turkey), xeno-free media optimized for proliferation and maturation of these cell lines, edible or biodegradable scaffolding for tissue engineering, and efficient bioreactors for cell proliferation and differentiation. While many biomedical products and tools can already be applied to the CTEs of clean meat, the opportunities to expand biomedical product lines are considerable. Large-scale cell culture for clean meat production presents a number of unique requirements that are not currently met with existing products for the biomedical industry. Namely, cost constraints and scale requirements for the clean meat industry are notably different than for cellular therapeutics or regenerative medicine, and innovation is needed to develop products that are optimized for the cell types and structures that are relevant for clean meat. Further, developing these tools for clean meat would simultaneously advance the technology and reduce costs for the biomedical and therapeutic applications. We will discuss new applications for current biomedical products and manufacturing methods for clean meat and discuss potential for symbiotic and synergistic product development through partnerships between researchers, biomedical product manufacturers, and the emergent clean meat industry

Opportunities to leverage cell culture technology to create sustainable food systems: The development of Clean Meat

Clean meat — meat produced through cell culture, rather than animal slaughter — can dramatically reduce the environmental footprint of meat while alleviating the severe public health threats and animal welfare concerns posed by factory farming. Recent developments in regenerative medicine, tissue engineering, and large-scale cell culture for cellular therapies have spawned a multitude of technologies that are immediately applicable to clean meat production. Many of these biomedical technologies and tools can already address areas of need within clean meat research and development, but large-scale cell culture for clean meat production presents a number of unique requirements that are not currently met with existing technologies developed for the biomedical, biopharma, and R&D industries. Most notably, cost constraints and scale requirements for the clean meat industry are significantly different than for cellular therapeutics or regenerative medicine, and innovation is needed to develop products that are optimized for the cell types and structures that are relevant for clean meat. Developing these tools for clean meat will simultaneously advance the technology and reduce costs for the biomedical and therapeutic applications. Please click Additional Files below to see the full abstract

Factors Associated with Revision Surgery after Internal Fixation of Hip Fractures

Background: Femoral neck fractures are associated with high rates of revision surgery after management with internal fixation. Using data from the Fixation using Alternative Implants for the Treatment of Hip fractures (FAITH) trial evaluating methods of internal fixation in patients with femoral neck fractures, we investigated associations between baseline and surgical factors and the need for revision surgery to promote healing, relieve pain, treat infection or improve function over 24 months postsurgery. Additionally, we investigated factors associated with (1) hardware removal and (2) implant exchange from cancellous screws (CS) or sliding hip screw (SHS) to total hip arthroplasty, hemiarthroplasty, or another internal fixation device. Methods: We identified 15 potential factors a priori that may be associated with revision surgery, 7 with hardware removal, and 14 with implant exchange. We used multivariable Cox proportional hazards analyses in our investigation. Results: Factors associated with increased risk of revision surgery included: female sex, [hazard ratio (HR) 1.79, 95% confidence interval (CI) 1.25-2.50; P = 0.001], higher body mass index (fo

Fracture fixation in the operative management of hip fractures (FAITH): an international, multicentre, randomised controlled trial

Background Reoperation rates are high after surgery for hip fractures. We investigated the effect of a sliding hip screw versus cancellous screws on the risk of reoperation and other key outcomes. Methods For this international, multicentre, allocation concealed randomised controlled trial, we enrolled patients aged 50 years or older with a low-energy hip fracture requiring fracture fixation from 81 clinical centres in eight countries. Patients were assigned by minimisation with a centralised computer system to receive a single large-diameter screw with a side-plate (sliding hip screw) or the present standard of care, multiple small-diameter cancellous screws. Surgeons and patients were not blinded but the data analyst, while doing the analyses, remained blinded to treatment groups. The primary outcome was hip reoperation within 24 months after initial surgery to promote fracture healing, relieve pain, treat infection, or improve function. Analyses followed the intention-to-treat principle. This study was registered with ClinicalTrials.gov, number NCT00761813. Findings Between Mar